Organisation paid for research Program year 2025 Source: CMS Open Payments

Mayo Clinic Pharmacy Subway

Neither a doctor nor a teaching hospital

Research payments

$3,716,092

391 payments

Through program year 2025, Mayo Clinic Pharmacy Subway is reported as receiving $3,716,092 in research payments, across 391 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $86,068 28
2024 Research $452,322 58
2023 Research $608,469 136
2022 Research $478,440 34
2021 Research $812,185 61
2020 Research $478,605 38
2019 Research $800,003 36

Breakdown

Who paid Research payments · program years 2019–2025
  1. Medtronic, Inc. $2,109,371 145 payments
  2. Medtronic Vascular, Inc. $1,277,708 73 payments
  3. Incyte Corporation $328,113 172 payments
  4. Medtronic USA, Inc. $900 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. TAVR Low Risk $1,784,701 70 payments
  2. Optimize Pro $978,820 62 payments
  3. APOLLO Trial $524,203 44 payments
  4. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva $95,026 79 payments
  5. A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) $65,080 14 payments
  6. A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) $58,411 16 payments
  7. A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) $43,206 34 payments
  8. Tavr 2.0 $39,120 24 payments
  9. A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT), B-MIND $35,611 6 payments
  10. EV ICD Pivotal $28,700 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record